中文 | English
Return
Total: 13 , 1/2
Show Home Prev Next End page: GO
MeSH:(Bone Density Conservation Agents/adverse effects/*therapeutic use)

1.Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ).

Ran YAN ; Ruixue JIANG ; Longwei HU ; Yuwei DENG ; Jin WEN ; Xinquan JIANG

International Journal of Oral Science 2022;14(1):41-41

2.Progress on medication-related osteonecrosis of the jaw.

Qi-Zhang WANG ; Ji-Yuan LIU ; Jian PAN

West China Journal of Stomatology 2018;36(5):568-572

3.Effect of alendronate on glucocorticoid-induced osteoporosis.

Xiaoling ZOU ; Qinxue LI ; Chunhua SHI

Journal of Central South University(Medical Sciences) 2009;34(6):563-565

4.Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia.

Ge SHEN ; San-tai SONG ; Ze-fei JIANG ; Shou-geng BIAN ; Guang-ru XIE ; Ya-jie WANG ; Jie-jun WANG

Chinese Journal of Oncology 2005;27(10):632-634

5.Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis.

Yuming, LI ; Zhongzhi, ZHANG ; Xiuling, DENG ; Lulu, CHEN

Journal of Huazhong University of Science and Technology (Medical Sciences) 2005;25(5):527-9

8.Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis.

Jun IWAMOTO ; Tsuyoshi TAKEDA ; Yoshihiro SATO ; Mitsuyoshi UZAWA

Yonsei Medical Journal 2005;46(6):750-758

9.A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer.

Sung Joon HONG ; Kang Su CHO ; Han Yong CHO ; Hanjong AHN ; Choung Soo KIM ; Byung Ha CHUNG

Yonsei Medical Journal 2007;48(6):1001-1008

10.Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management.

Boon Hui CHAN ; Ruixiang YEE ; Rukshini PUVANENDRAN ; Seng Bin ANG

Singapore medical journal 2018;59(2):70-75

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 13 , 1/2 Show Home Prev Next End page: GO